TEST:

Foresight CLARITY™

Median prior lines of therapy was 3 (range 2–12), 18 (38%) pts received prior lenalidomide–based therapy, 7 (15%) pts received prior chimeric antigen receptor T-cell therapy (CAR-T), and 4 (9%) received prior CD20 TCE therapy. AZD0486 offers high response rates in pts with R/R FL at target doses ≥2.4 mg. Responses were durable. 2SUD allows safe administration of the target dose up to at least 15 mg.

"Foresight Diagnostics founders Maximilian Diehn and Arash Ash Alizadeh, as individuals, said in a court document filed on Wednesday in the US District Court for the Northern District of California that the claims made by Roche in a lawsuit concerning trade secrets are meritless and untimely."

"Foresight Diagnostics...announced an upcoming presentation featuring its Foresight CLARITY MRD platform at the ESMO Congress 2024 on September 16 in Barcelona, Spain...In collaboration with Memorial Sloan Kettering Cancer Center (MSK) and Stanford University, the study will showcase the clinical performance of Foresight CLARITY for MRD-based recurrence detection in early-stage breast cancer patients from MSK’s Liquid Biopsy for INterception of Cancer (MSK-LINC) study...It is designed to assess the utility of MRD detection and monitoring during and after curative-intent therapy in enabling earlier treatment interventions and improving outcomes for patients with early-stage solid tumor cancers...The full data have been submitted for presentation at the ESMO Congress 2024."

"Foresight Diagnostics, Inc...announced the closing of $33 million in new capital from existing investors Foresite Capital, Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and University of Colorado Healthcare Innovation Fund. The additional funds will support advancement of Foresight CLARITY, the Company’s ultrasensitive liquid biopsy MRD testing platform in lymphoma, in addition to solid tumor evidence generation. To date, the company has raised $86 million in venture financing."

"Foresight Diagnostics...announced its upcoming poster presentation at the 2024 American Society of Clinical Oncology (ASCO®) Annual Meeting. In partnership with Memorial Sloan Kettering Cancer Center and Stanford University, this study showcases the improved sensitivity and superior clinical performance of MRD detection by Foresight CLARITY™ in early-stage non-small cell lung cancer (NSCLC) within the post-operative adjuvant setting as compared to MRD detection by conventional liquid biopsy-based methods."